ClinicalTrials.gg
RecruitingNCT07226726Updated Oct 16, 2026

Patients With Congenital Myasthenic Syndrome Will be Treated With Umbilical or Placental Derived Mesenchymal Stem Cell Exosome Solution

A Phase 1 interventional study of AlloEx exosomes in Congenital Myasthenic Syndrome, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2025, registered Nov 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Oct 16, 2026First site in GreeceNo longer in Antigua and Barbuda+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients with Congenital Myasthenic Syndrome will be treated with Umbilical or Placental Derived Mesenchymal Stem Cell Exosome solution.

Read the detailed description

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

02

Conditions studied

  • Congenital Myasthenic Syndrome

Keywords

  • exosomes
  • secretome
  • Congenital Myasthenic Syndrome
03

In context

Lead sponsor

The Foundation for Orthopaedics and Regenerative Medicine is the lead sponsor of 33 studies on the registry; 19 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
  • Patients must be able to provide , or have a guardian who does.
  • Patient must be able to travel to the site of treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded from the trial if they are pregnant or have active cancer () at the screening consultation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Biological: AlloEx exosomes

Interventions

  • BiologicalAlloEx exosomes

    This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

06

What researchers measure

Primary outcomes

  1. Oxygen Saturation

    Time frame: From enrollment to 6 months after treatment

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2028, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2025
First posted
Nov 10, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 2 sites removed — first site in Greece; no longer in Antigua and Barbuda
Show site
  • Prodromos Stem Cell Institute · Athens, Greece
Show 2 removed
  • Prodromos Stem Cell Institute · Irving, United States
  • Medical Surgical Associates Center · St John's, Antigua and Barbuda
Oct 16, 2026
Contact
Study contact's phone or email changed: •••6810→•••6810. See the current contact
Oct 16, 2026
Title
Patients With Congenital Myasthenic Syndrome Will be Treated With Umbilical or Placental Derived Mesenchymal Stem Cell Exosome Solution
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site added, 2 sites removed — first site in Greece; no longer in Antigua and Barbuda
    Show site
    • Prodromos Stem Cell Institute · Athens, Greece
    Show 2 removed
    • Prodromos Stem Cell Institute · Irving, United States
    • Medical Surgical Associates Center · St John's, Antigua and Barbuda
    Contact Study contact's phone or email changed: •••6810→•••6810. See the current contact
    Title Patients With Congenital Myasthenic Syndrome Will be Treated With Umbilical or Placental Derived Mesenchymal Stem Cell Exosome Solution
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07226726
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Jan 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Chadwick Prodromos
Contact
care@thepsci.com
847-699-6810 ext. 202

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion